Why Express Scripts Is Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmacy benefit manager Express Scripts has earned a respected four-star ranking.
With that in mind, let's take a closer look at Express Scripts and see what CAPS investors are saying about the stock right now.
St. Louis (1986)
Chairman/CEO George Paz
CFO Jeffrey Hall
Return on Equity (average, past 3 years)
Cash / Debt
$1.3 billion / $17.1 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 795 members who have rated Express Scripts believe the stock will outperform the S&P 500 going forward.
[T]he synergies of the Medco merger are paying off handsomely, and Express Scripts will benefit from health care reform. The market has over-reacted to management talk of "overly aggressive" forecasts. Other than that [faux pas], management has been exemplary and will take the company forward to a very bright future.
Want a closer look at Express Scripts? In the Fool's brand new premium report on Express Scripts, Stock Advisor analyst Jim Mueller dives deep into the company's prospects. Here's a hint: There's plenty of room for growth. You'll understand why, along with an outline of the key must-watch areas of the company, if you claim a copy by clicking here now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Express Scripts Is Poised to Outperform originally appeared on Fool.com.Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of Catamaran and Express Scripts. Motley Fool newsletter services recommend Catamaran and Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.